Form 8-K - Current report:
SEC Accession No. 0001558370-25-002859
Filing Date
2025-03-13
Accepted
2025-03-13 08:27:20
Documents
17
Period of Report
2025-03-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mgtx-20250309x8k.htm   iXBRL 8-K 56333
2 EX-99.1 mgtx-20250309xex99d1.htm EX-99.1 35652
3 EX-99.2 mgtx-20250309xex99d2.htm EX-99.2 211290
4 GRAPHIC mgtx-20250309xex99d1001.jpg GRAPHIC 3029
5 GRAPHIC mgtx-20250309xex99d2002.jpg GRAPHIC 4968
  Complete submission text file 0001558370-25-002859.txt   471977

Data Files

Seq Description Document Type Size
6 EX-101.SCH mgtx-20250309.xsd EX-101.SCH 3122
7 EX-101.LAB mgtx-20250309_lab.xml EX-101.LAB 15929
8 EX-101.PRE mgtx-20250309_pre.xml EX-101.PRE 10054
19 EXTRACTED XBRL INSTANCE DOCUMENT mgtx-20250309x8k_htm.xml XML 4815
Mailing Address 450 EAST 29TH STREET 14TH FLOOR NEW YORK NY 10016
Business Address 450 EAST 29TH STREET 14TH FLOOR NEW YORK NY 10016 646-860-7985
MeiraGTx Holdings plc (Filer) CIK: 0001735438 (see all company filings)

EIN.: 981448305 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38520 | Film No.: 25733926
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)